These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 27885796)
1. Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis. Aigelsreiter A; Neumann J; Pichler M; Halasz J; Zatloukal K; Berghold A; Douschan P; Rainer F; Stauber R; Haybaeck J; Denk H; Lackner C Liver Int; 2017 Apr; 37(4):600-610. PubMed ID: 27885796 [TBL] [Abstract][Full Text] [Related]
2. Cross β-sheet conformation of keratin 8 is a specific feature of Mallory-Denk bodies compared with other hepatocyte inclusions. Mahajan V; Klingstedt T; Simon R; Nilsson KP; Thueringer A; Kashofer K; Haybaeck J; Denk H; Abuja PM; Zatloukal K Gastroenterology; 2011 Sep; 141(3):1080-1090.e1-7. PubMed ID: 21699779 [TBL] [Abstract][Full Text] [Related]
3. In vitro production of Mallory bodies and intracellular hyaline bodies: the central role of sequestosome 1/p62. Stumptner C; Fuchsbichler A; Zatloukal K; Denk H Hepatology; 2007 Sep; 46(3):851-60. PubMed ID: 17685470 [TBL] [Abstract][Full Text] [Related]
4. Are the Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic hepatocytes related? Denk H; Stumptner C; Fuchsbichler A; Müller T; Farr G; Müller W; Terracciano L; Zatloukal K J Pathol; 2006 Apr; 208(5):653-61. PubMed ID: 16477590 [TBL] [Abstract][Full Text] [Related]
5. The genetic background modulates susceptibility to mouse liver Mallory-Denk body formation and liver injury. Hanada S; Strnad P; Brunt EM; Omary MB Hepatology; 2008 Sep; 48(3):943-52. PubMed ID: 18697208 [TBL] [Abstract][Full Text] [Related]
6. From Mallory to Mallory-Denk bodies: what, how and why? Zatloukal K; French SW; Stumptner C; Strnad P; Harada M; Toivola DM; Cadrin M; Omary MB Exp Cell Res; 2007 Jun; 313(10):2033-49. PubMed ID: 17531973 [TBL] [Abstract][Full Text] [Related]
7. Analysis of intracytoplasmic hyaline bodies in a hepatocellular carcinoma. Demonstration of p62 as major constituent. Stumptner C; Heid H; Fuchsbichler A; Hauser H; Mischinger HJ; Zatloukal K; Denk H Am J Pathol; 1999 Jun; 154(6):1701-10. PubMed ID: 10362795 [TBL] [Abstract][Full Text] [Related]
8. Autophagy activation by rapamycin eliminates mouse Mallory-Denk bodies and blocks their proteasome inhibitor-mediated formation. Harada M; Hanada S; Toivola DM; Ghori N; Omary MB Hepatology; 2008 Jun; 47(6):2026-35. PubMed ID: 18454506 [TBL] [Abstract][Full Text] [Related]
9. Autophagy is involved in the elimination of intracellular inclusions, Mallory-Denk bodies, in hepatocytes. Harada M Med Mol Morphol; 2010 Mar; 43(1):13-8. PubMed ID: 20340001 [TBL] [Abstract][Full Text] [Related]
10. p62/Sequestosome-1 Is Indispensable for Maturation and Stabilization of Mallory-Denk Bodies. Lahiri P; Schmidt V; Smole C; Kufferath I; Denk H; Strnad P; Rülicke T; Fröhlich LF; Zatloukal K PLoS One; 2016; 11(8):e0161083. PubMed ID: 27526095 [TBL] [Abstract][Full Text] [Related]
11. Identification of p62, a phosphotyrosine independent ligand of p56lck kinase, as a major component of intracytoplasmic hyaline bodies in hepatocellular carcinoma. Stumptner C; Heid H; Zatloukal K; Fuchsbichler A; Hauser H; Denk H Verh Dtsch Ges Pathol; 1999; 83():254-9. PubMed ID: 10714219 [TBL] [Abstract][Full Text] [Related]
12. Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory-Denk bodies. Ku NO; Strnad P; Zhong BH; Tao GZ; Omary MB Hepatology; 2007 Nov; 46(5):1639-49. PubMed ID: 17969036 [TBL] [Abstract][Full Text] [Related]
13. "Toxic memory" via chaperone modification is a potential mechanism for rapid Mallory-Denk body reinduction. Strnad P; Tao GZ; So P; Lau K; Schilling J; Wei Y; Liao J; Omary MB Hepatology; 2008 Sep; 48(3):931-42. PubMed ID: 18697205 [TBL] [Abstract][Full Text] [Related]
14. p62/SQSTM1 in liver diseases: the usual suspect with multifarious identities. Tan CT; Soh NJH; Chang HC; Yu VC FEBS J; 2023 Feb; 290(4):892-912. PubMed ID: 34882306 [TBL] [Abstract][Full Text] [Related]
15. Sequestosome 1/p62-related pathways as therapeutic targets in hepatocellular carcinoma. Denk H; Stumptner C; Abuja PM; Zatloukal K Expert Opin Ther Targets; 2019 May; 23(5):393-406. PubMed ID: 30987486 [TBL] [Abstract][Full Text] [Related]